Chemistry:Elunetirom
Elunetirom, also known by its developmental code names ABX-002 and MA-JD21, is a thyroid hormone receptor agonist which is under development for the treatment of major depressive disorder, bipolar depression, multiple sclerosis, and adrenomyeloneuropathy.[1][2] It is a prodrug of LL-340001 and acts as a potent, selective, and centrally penetrant agonist of the thyroid hormone receptor beta (TRβ).[1][2] The drug produces psychoplastogenic effects similar to those of brain-derived neurotrophic factor (BDNF) in rodents.[2] In addition, it has been found to improve cognitive impairment caused by old age or scopolamine treatment in rodents.[2] Eunetirom is under development by Autobahn Therapeutics.[1] As of December 2025, it is in phase 2 clinical trials for treatment of major depressive disorder and bipolar depression and is in the preclinical research stage of development for multiple sclerosis and adrenomyeloneuropathy.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "Autobahn Therapeutics". 2 December 2025. https://adisinsight.springer.com/drugs/800059037.
- ↑ 2.0 2.1 2.2 2.3 "ACNP 64th Annual Meeting: Poster Abstracts P584-P872". Neuropsychopharmacology (Nature Publishing Group) 51 (Suppl 1): 410–571. January 2026. doi:10.1038/s41386-025-02281-2. PMID 41507446.
 |  |
